Abbott Laboratories

ABT

买入
2026年7月27日Neutral

决策摘要

Abbott (ABT) closed at $104.49 on July 27, 2026, up 12.9% over the past month following the Q2 2026 earnings beat and raised full-year guidance. The at 18.67 indicates a neutral market regime, while the 10-year yield at 4.64% continues to pressure defensive multiples, though ABT's low forward of 17.2x provides a margin of safety. The fundamental thesis strengthened with Q2 adjusted of $1.31 beating by 2.3%, revenue up 13% YoY to $12.59B, and full-year guidance raised to $5.45-$5.60. Growth is driven by Medical Devices (+8.4% comparable) and Cancer Diagnostics (+13.3% comparable), while Nutrition trends are improving sequentially. The balance sheet remains solid with $7.3B cash and $34.1B debt. Technically, the stock is above ($95.94) and ($94.18) with a bullish and expanding histogram, but at 70.2 is overbought, suggesting potential for short-term consolidation. Post-earnings, multiple analysts raised price targets, with the mean target of $119.13 implying 14% upside. Estimate revisions for FY2026 have turned positive, though current quarter saw a slight trim. Insider activity remains strongly bullish with CEO purchases totaling $23M. The primary risk is NEC litigation, but a DOJ policy shift may reduce liability. Overall, the setup remains attractive for long-term investors, with near-term caution warranted due to overbought conditions.

投资判断

实时价格

$104.49

推荐分数

86%
86%

置信度

85%
85%

各期限展望

1个月

买入

短线

6个月

买入

中期

1年

强力买入

长期

核心催化

Q2 earnings beat and raised guidance triggered a 10.7% single-day surge, reinforcing the operational turnaround narrative.

稳定性分类Defensive Compounder组合角色Core Anchor回撤风险Medium风险画像ModerateDividend KingInsider BuyingMedTech AccelerationEarnings BeatGuidance RaisedTechnical BreakoutPost-Earnings MomentumUndervaluedLitigation Overhang
决策工作台

价格地图

60日设置

价格轨道

$104.49
止损
当前
$90
$101
$111
$122
止损位

$93.00

买入

$100.00 - $102.00

止盈

$106.96 - $119.13

风险/回报

1.5x

控制仓位

到止损下行

-11.0%

到止盈上行

+14.0%

仓位提示

Full position sizing is appropriate given the neutral and strong post-earnings clarity. However, maintain a stop loss to protect against adverse litigation news or market selloff. Consider reducing to 75% if rises above 25 or litigation escalates.

投资逻辑快照

什么情况涨

ABT is a Dividend King at a cheap forward of ~17x, with accelerating growth from Medical Devices and Cancer Diagnostics. The CEO's $23M insider purchase underscores conviction. If NEC litigation is resolved favorably, re-rating to 20x+ implies $120+. Technical breakout on huge volume confirms institutional accumulation.

什么情况跌

NEC litigation outcomes remain uncertain; worst-case liability could exceed $10B, impairing balance sheet and dividend. High interest rates may compress multiples further. Nutrition weakness may persist. The stock is still below , indicating long-term trend not yet bullish. Limited upside per some targets (~$108 per Zacks).

A daily close below $92.00 (below and major support) or a significant adverse NEC court ruling that increases estimated liability by >$5B, or a downward guidance revision on next earnings call.

  • NEC litigation liability could be material and uncapped
  • High interest rates (10Y near 4.64%) compress defensive multiples
  • Integration and cost execution risk from Exact Sciences acquisition
  • Competition in CGM from Dexcom and others
  • Potential slowdown in U.S. procedure volumes if macro weakens

接下来关注

  • 下一次财报：2026年10月14日
  • Q2 earnings beat and raised guidance triggered a 10.7% single-day surge, reinforcing the operational turnaround narrative.
信号仪表盘

决策输入

6 个信号

基本面

14.0%

距分析师均值目标空间

ABT trades at 17.2x forward , a significant discount to its 5-year median of approximately 23x and to the broader healthcare sector. The ratio of 2.08 is above the 1.5x threshold but justified by durable growth and strong FCF generation. of 17.4x is in line with historical averages. Given raised guidance, the stock appears undervalued relative to intrinsic value.

技术面

Bullish

趋势质量

Short-term trend is strongly bullish, with price ($104.49) above ($95.94) and ($94.18), both sloping upward. The has recently crossed above ? Actually, is above , indicating near-term momentum acceleration. Long-term trend remains bearish with price below ($106.96), but the gap is narrowing. Trend is transitioning from downtrend to potential uptrend.

财报

78天

Accelerating

Q2 2026 adjusted of $1.31 beat consensus by 2.3%, revenue exceeded by 0.9%, and full-year guidance was raised to $5.45-$5.60. The market reacted positively with a 10.7% surge on the release day.

新闻

Bullish

新闻基调

Q2 earnings beat and raised guidance triggered a 10.7% single-day surge, reinforcing the operational turnaround narrative.

宏观

Neutral

4.64% 10Y / 18.7 VIX

Elevated 10Y yield (4.64%) continues to pressure defensive valuations, but ABT's low forward (17.2x) and robust company-specific drivers (earnings beat, raised guidance, MedTech acceleration) partially insulate the stock from macro headwinds.

稳定性

Defensive Compounder

Core Anchor

Abbott's diversified healthcare portfolio, essential product lines, and 54-year dividend growth streak make it a core defensive holding. While litigation and interest rate risks present medium-term drawdown potential, the business quality and cash flow stability support high thesis durability. The stock should serve as a foundation in a diversified portfolio.

分析师目标区间

均值目标

$119.13

高低目标

$103 / $135

分析师中值目标

$119.00

共识区间

$103 - $135

— 位分析师
Mean
$103$119$135

市场共识

Mean target of $119.13 implies 14% upside from current price. Wide spread ($103 low to $135 high) reflects uncertainty around litigation and nutrition, but recent upward revisions suggest growing confidence. The low target has been essentially met, likely to be raised.

筹码脉冲

内部人信号

Strong Buy

净偏向

Buy-heavy

内部人持股

0.5%

机构持股

82.5%

解读

Management's substantial personal investment signals strong confidence in the turnaround and undervaluation.

重要活动

CEO Robert Ford executed two open-market purchases totaling approximately $23.2 million in late April/early May 2026, near the stock's low. No significant insider sales have been recorded. A small purchase by an officer also occurred.

市场背景

行业

Medical Devices

Bullish

情绪

63

跟踪股票

1

分组

industry

Medical Devices 行业 当前情绪为 Bullish，板块平均评分约 86 分，整体偏稳，且leadership is still concentrated。

轮动线索

  • Medical Devices 行业 组内评分变化不大，当前更像是存量博弈。
  • 当前组内偏多评级 1 只，偏空评级 0 只，可见情绪主导方向为 Bullish。

重点龙头股

相关龙头股

当前还没有其他已跟踪龙头股。

主题

MedTech & Diagnostics Renaissance

评分: 85

Bullish

Abbott's pivot to higher-margin Medical Devices and Diagnostics is driving accelerating growth, confirmed by Q2 results. New product launches and expanding CGM reimbursement support sustained momentum. This theme is strengthening, though the elevated tempers near-term enthusiasm.

Q2 earnings beat and raised guidance confirm operational acceleration.

  • Strong comparable sales in Medical Devices and Diagnostics
  • New product pipeline (Amulet 360, Volt, Libre Duo)
关键指标
23 项指标

市值

$182.00B

市盈率 (TTM)

33.8

远期市盈率

17.2

营收增速

13.0%

净资产收益率

0.0%

Beta 系数

0.61

完整指标集

另外 17 项指标

估值结构

估值倍数与现金流框架。

市销率

3.9

市净率

3.5

企业价值 / EBITDA

17.4

质量与资产负债表

利润率、杠杆与流动性。

毛利率

56.8%

营业利润率

14.2%

资产负债率

64.8

流动比率

0.00x

速动比率

0.00x

仓位与价格区间

空头仓位与52周区间位置。

流通盘空头占比

1.6%

空头回补天数

1.83x

52周最高

$137.49

52周最低

$81.97

距52周高点

-24.0%

距52周低点

27.5%

公司分类

板块与行业背景。

板块

Healthcare

行业

Medical Devices

其他信号

自由现金流

$0.00

详细分析
估值
ABT trades at 17.2x forward , a significant discount to its 5-year median of approximately 23x and to the broader healthcare sector. The ratio of 2.08 is above the 1.5x threshold but justified by durable growth and strong FCF generation. of 17.4x is in line with historical averages. Given raised guidance, the stock appears undervalued relative to intrinsic value.
资产负债表
Balance sheet is solid with manageable leverage ( 64.8%) and substantial liquidity. Net debt is about 15% of market cap. Cash flow generation is robust, easily covering interest and dividends. The company has capacity for M&A and consistent dividend growth.
增长
Revenue growth of 13% reported is strong, with comparable sales up 4.8% reflecting underlying momentum in Medical Devices (+8.4% comparable), Diagnostics (+42% reported, with Cancer Diagnostics +13.3% comparable), and Established Pharmaceuticals (+8.7% comparable). These gains offset Nutrition headwinds. Management expects growth to accelerate in H2 2026, supported by new product launches (Amulet 360, Volt, Libre Duo). Long-term growth drivers include aging demographics, CGM adoption, and cancer screening expansion.

生意质量

Gross margin 56.8%, operating margin 14.2%, margin 25.5% reflect strong pricing power and scale advantages. The diversified portfolio spans durable moats in diabetes, diagnostics, nutrition, and pharmaceuticals. R&D investment supports innovation. Business quality is high, warranting a premium valuation.

资本配置

Capital allocation prioritizes dividend growth (54-year streak), strategic M&A (Exact Sciences), and organic R&D. CEO's $23M open-market insider purchase signals confidence. Dividend yield of 2.45% is well-covered. Capital deployment is disciplined and shareholder-friendly.

预期修正

Estimate revisions show a mixed picture: current quarter (Q3 2026) saw a slight trim of $0.004 over the past week, but next quarter (+1q) and full-year FY2026 estimates have been revised upward over the past 30 days. Post-earnings, several analysts raised price targets, and the consensus remains heavily buy-skewed (20 strong buy/buy vs 7 hold). The revision momentum is shifting positive for the full year.

营收增速

13.0%

实时动态与情绪

内部活动

  • EARNHARDT LISA D

    Officer

    22,852

    $2.4M

  • FUNCK ROBERT E. JR.

    Officer

    10,097

    $475k

  • FUNCK ROBERT E. JR.

    Officer

    10,097

    $1.1M

  • MCCOY JOHN A. JR

    Officer

    27

    $3k

新闻催化剂

2026年7月27日

Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth?

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper […]

2026年7月27日

Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth

Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]

2026年7月27日

Is Abbott Stock Attractive After Its Earnings and Guidance Update?

ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?

2026年7月27日

Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson

GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.